Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
- Symposium Session Draws Leading Experts to Review Recent Developments in Cardiac Regenerative Therapies
Cardio3 BioSciences, today provided an update and review of the clinical
development of its unique C-Cure(R) therapy at the European Society of
Cardiology Congress in
The update was part of a broader satellite symposium at the Congress led by a panel of expert speakers. In addition to reviewing C-Cure the distinguished panel traced the progress made in the development of regenerative therapies for heart failure from first generation to second generation products.
The session was led by Prof.
C-Cure draws on an unrivalled understanding of the fundamental science of heart cell development at the Mayo Clinic and within the Cardio3 BioSciences scientific in-house team. The product involves taking a patient's own bone marrow cells and through a proprietary culturing technology, gives rise to 'cardiopoietic' cells that can regenerate damaged heart muscle. Unlike previous cell therapies for this indication, C-Cure is designed to produce new autologous heart muscle cells which behave identically to those lost in infarction without carrying the risk of rejection.
About Cardio3 BioSciences
Cardio3 BioSciences is a leading Belgian biotechnology company specialising in stem cell-based therapies for the treatment of cardiovascular disease. The Company's lead product, C-Cure, is a highly innovative approach to the treatment of heart failure, one of the world's most pressing unmet medical needs. Based on a strategy developed by Cardio3 BioSciences' founders and leveraging technology from Mayo Clinic, C-Cure allows the differentiation of a patient's own cells into 'cardiopoeitic' cells which grow into new heart cells and repair heart muscle.
The Cardio3 BioSciences team has extensive experience in developing and
commercialising new pharmaceutical products and medical technologies and the
Company's strategy is to drive the clinical development of C-Cure and to
market the product itself in major territories. Cardio3 BioSciences was
For more information contact: Cardio3 BioSciences Mayra Beydoun, Brand & Communication Manager Tel : +32-10-39-41-00 email@example.com http://www.c3bs.com Citigate Dewe Rogerson Chris Gardner/Nina Enegren Tel : +44(0)207-638-9571 firstname.lastname@example.org email@example.com
SOURCE Cardio3 BioSciences
More by this Source
Cardio3 BioSciences C-Cath® Article Published in Circulation Cardiovascular Interventions
Dec 11, 2013, 12:00 ET
Cardio3 BioSciences Partner and Exploitation Manager of a Eur 4.5 Million FP7 Research Grant
Nov 25, 2013, 05:49 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.